MR Microimaging of amyloid plaques in Alzheimer's disease transgenic mice

Thomas M. Wengenack, Clifford R Jr. Jack, Michael Garwood, Joseph F. Poduslo

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Introduction: Alzheimer's disease (AD) is the most prevalent neurological condition affecting industrialized nations and will rapidly become a healthcare crisis as the population ages. Currently, the post-mortem histological observation of amyloid plaques and neurofibrillary tangles is the only definitive diagnosis available for AD. A pre-mortem biological or physiological marker specific for AD used in conjunction with current neurological and memory testing could add a great deal of confidence to the diagnosis of AD and potentially allow therapeutic intervention much earlier in the disease process. Discussion and conclusion: Our group has developed MRI techniques to detect individual amyloid plaques in AD transgenic mouse brain in vivo. We are also developing contrast-enhancing agents to increase the specificity of detection of amyloid plaques. Such in vivo imaging of amyloid plaques will also allow the evaluation of anti-amyloid therapies being developed by the pharmaceutical industry in pre-clinical trials of AD transgenic mice. This short review briefly discusses our progress in these areas.

Original languageEnglish (US)
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume35
Issue numberSUPPL. 1
DOIs
StatePublished - Mar 2008

Fingerprint

Amyloid Plaques
Transgenic Mice
Alzheimer Disease
Neurofibrillary Tangles
Drug Industry
Developed Countries
Amyloid
Contrast Media
Observation
Clinical Trials
Delivery of Health Care
Brain
Therapeutics
Population

Keywords

  • Alzheimer's disease
  • Amyloid-β
  • Magnetic resonance imaging
  • Plaque
  • Transgenic mouse

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

MR Microimaging of amyloid plaques in Alzheimer's disease transgenic mice. / Wengenack, Thomas M.; Jack, Clifford R Jr.; Garwood, Michael; Poduslo, Joseph F.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 35, No. SUPPL. 1, 03.2008.

Research output: Contribution to journalArticle

@article{19d7529b39d9474a8e6f802ae66bd17b,
title = "MR Microimaging of amyloid plaques in Alzheimer's disease transgenic mice",
abstract = "Introduction: Alzheimer's disease (AD) is the most prevalent neurological condition affecting industrialized nations and will rapidly become a healthcare crisis as the population ages. Currently, the post-mortem histological observation of amyloid plaques and neurofibrillary tangles is the only definitive diagnosis available for AD. A pre-mortem biological or physiological marker specific for AD used in conjunction with current neurological and memory testing could add a great deal of confidence to the diagnosis of AD and potentially allow therapeutic intervention much earlier in the disease process. Discussion and conclusion: Our group has developed MRI techniques to detect individual amyloid plaques in AD transgenic mouse brain in vivo. We are also developing contrast-enhancing agents to increase the specificity of detection of amyloid plaques. Such in vivo imaging of amyloid plaques will also allow the evaluation of anti-amyloid therapies being developed by the pharmaceutical industry in pre-clinical trials of AD transgenic mice. This short review briefly discusses our progress in these areas.",
keywords = "Alzheimer's disease, Amyloid-β, Magnetic resonance imaging, Plaque, Transgenic mouse",
author = "Wengenack, {Thomas M.} and Jack, {Clifford R Jr.} and Michael Garwood and Poduslo, {Joseph F.}",
year = "2008",
month = "3",
doi = "10.1007/s00259-007-0706-9",
language = "English (US)",
volume = "35",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
issn = "1619-7070",
publisher = "Springer Verlag",
number = "SUPPL. 1",

}

TY - JOUR

T1 - MR Microimaging of amyloid plaques in Alzheimer's disease transgenic mice

AU - Wengenack, Thomas M.

AU - Jack, Clifford R Jr.

AU - Garwood, Michael

AU - Poduslo, Joseph F.

PY - 2008/3

Y1 - 2008/3

N2 - Introduction: Alzheimer's disease (AD) is the most prevalent neurological condition affecting industrialized nations and will rapidly become a healthcare crisis as the population ages. Currently, the post-mortem histological observation of amyloid plaques and neurofibrillary tangles is the only definitive diagnosis available for AD. A pre-mortem biological or physiological marker specific for AD used in conjunction with current neurological and memory testing could add a great deal of confidence to the diagnosis of AD and potentially allow therapeutic intervention much earlier in the disease process. Discussion and conclusion: Our group has developed MRI techniques to detect individual amyloid plaques in AD transgenic mouse brain in vivo. We are also developing contrast-enhancing agents to increase the specificity of detection of amyloid plaques. Such in vivo imaging of amyloid plaques will also allow the evaluation of anti-amyloid therapies being developed by the pharmaceutical industry in pre-clinical trials of AD transgenic mice. This short review briefly discusses our progress in these areas.

AB - Introduction: Alzheimer's disease (AD) is the most prevalent neurological condition affecting industrialized nations and will rapidly become a healthcare crisis as the population ages. Currently, the post-mortem histological observation of amyloid plaques and neurofibrillary tangles is the only definitive diagnosis available for AD. A pre-mortem biological or physiological marker specific for AD used in conjunction with current neurological and memory testing could add a great deal of confidence to the diagnosis of AD and potentially allow therapeutic intervention much earlier in the disease process. Discussion and conclusion: Our group has developed MRI techniques to detect individual amyloid plaques in AD transgenic mouse brain in vivo. We are also developing contrast-enhancing agents to increase the specificity of detection of amyloid plaques. Such in vivo imaging of amyloid plaques will also allow the evaluation of anti-amyloid therapies being developed by the pharmaceutical industry in pre-clinical trials of AD transgenic mice. This short review briefly discusses our progress in these areas.

KW - Alzheimer's disease

KW - Amyloid-β

KW - Magnetic resonance imaging

KW - Plaque

KW - Transgenic mouse

UR - http://www.scopus.com/inward/record.url?scp=41149130103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41149130103&partnerID=8YFLogxK

U2 - 10.1007/s00259-007-0706-9

DO - 10.1007/s00259-007-0706-9

M3 - Article

VL - 35

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

IS - SUPPL. 1

ER -